133 related articles for article (PubMed ID: 21404005)
1. A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma.
Joensson P; Hotz B; Buhr HJ; Hotz HG
Langenbecks Arch Surg; 2011 Apr; 396(4):535-41. PubMed ID: 21404005
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
3. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
[TBL] [Abstract][Full Text] [Related]
5. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
Hotz HG; Hines OJ; Hotz B; Foitzik T; Buhr HJ; Reber HA
J Gastrointest Surg; 2003 Feb; 7(2):220-7; discussion 227-8. PubMed ID: 12600446
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
Hotz HG; Reber HA; Hotz B; Sanghavi PC; Yu T; Foitzik T; Buhr HJ; Hines OJ
J Gastrointest Surg; 2001; 5(2):131-8. PubMed ID: 11331474
[TBL] [Abstract][Full Text] [Related]
8. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.
Tepel J; Kruse ML; Kapischke M; Haye S; Sipos B; Kremer B; Kalthoff H
Pancreatology; 2006; 6(3):240-7. PubMed ID: 16543775
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC).
Hiroshima Y; Maawy A; Zhang Y; Murakami T; Momiyama M; Mori R; Matsuyama R; Chishima T; Tanaka K; Ichikawa Y; Endo I; Hoffman RM; Bouvet M
Pancreatology; 2015; 15(3):295-301. PubMed ID: 25800176
[TBL] [Abstract][Full Text] [Related]
11. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.
Hotz HG; Gill PS; Masood R; Hotz B; Buhr HJ; Foitzik T; Hines OJ; Reber HA
J Gastrointest Surg; 2002; 6(2):159-66; discussion 166. PubMed ID: 11992800
[TBL] [Abstract][Full Text] [Related]
12. Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score-Matched Analysis.
Lee SH; Hwang HK; Kang CM; Lee WJ
Integr Cancer Ther; 2019; 18():1534735418816825. PubMed ID: 30501431
[TBL] [Abstract][Full Text] [Related]
13. Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models.
Maawy AA; Hiroshima Y; Zhang Y; Garcia-Guzman M; Luiken GA; Kobayashi H; Hoffman RM; Bouvet M
J Surg Res; 2015 Jul; 197(1):5-11. PubMed ID: 25799527
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
16. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.
Büchler P; Reber HA; Roth MM; Shiroishi M; Friess H; Hines OJ
Neoplasia; 2007 Feb; 9(2):119-27. PubMed ID: 17356708
[TBL] [Abstract][Full Text] [Related]
17. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer.
Hotz HG; Reber HA; Hotz B; Yu T; Foitzik T; Buhr HJ; Cortina G; Hines OJ
Pancreas; 2003 May; 26(4):e89-98. PubMed ID: 12717279
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
20. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
